Boston Scientific (BSX) closed the most recent trading day at $92.51, moving +1.34% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.03% for the day. At the same time, the Dow lost 0.58%, and the tech-heavy Nasdaq gained 0.28%.
Shares of the medical device manufacturer have depreciated by 5.03% over the course of the past month, underperforming the Medical sector's loss of 0.01%, and the S&P 500's gain of 0.6%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on February 4, 2026. The company is expected to report EPS of $0.78, up 11.43% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $5.27 billion, showing a 15.44% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.04 per share and a revenue of $20.06 billion, signifying shifts of +21.12% and 0%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Boston Scientific holds a Zacks Rank of #2 (Buy).
From a valuation perspective, Boston Scientific is currently exchanging hands at a Forward P/E ratio of 26.43. This denotes a premium relative to the industry average Forward P/E of 20.37.
Also, we should mention that BSX has a PEG ratio of 1.62. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 1.72 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
